Robert W. Baird Increases DexCom (NASDAQ:DXCM) Price Target to $240.00

Share on StockTwits

DexCom (NASDAQ:DXCM) had its price objective raised by analysts at Robert W. Baird from $195.00 to $240.00 in a note issued to investors on Thursday, The Fly reports. The brokerage currently has an “outperform” rating on the medical device company’s stock. Robert W. Baird’s target price indicates a potential upside of 21.16% from the stock’s current price.

Other analysts also recently issued research reports about the company. Piper Jaffray Companies set a $182.00 target price on DexCom and gave the stock a “buy” rating in a research note on Monday, September 23rd. Oppenheimer upped their target price on DexCom from $167.00 to $180.00 in a research note on Thursday, August 1st. BMO Capital Markets upped their target price on DexCom from $180.00 to $190.00 and gave the stock an “outperform” rating in a research note on Tuesday, September 3rd. BidaskClub upgraded DexCom from a “hold” rating to a “buy” rating in a research note on Friday, November 1st. Finally, Zacks Investment Research upgraded DexCom from a “hold” rating to a “buy” rating and set a $154.00 target price on the stock in a research note on Friday, October 25th. Five investment analysts have rated the stock with a hold rating and fourteen have given a buy rating to the company’s stock. The company currently has an average rating of “Buy” and a consensus target price of $190.67.

Shares of DXCM traded up $3.38 during trading hours on Thursday, hitting $198.08. The company had a trading volume of 2,580,200 shares, compared to its average volume of 1,138,483. DexCom has a one year low of $105.05 and a one year high of $200.80. The company has a current ratio of 6.05, a quick ratio of 5.64 and a debt-to-equity ratio of 1.56. The company has a market capitalization of $14.00 billion, a PE ratio of 660.27 and a beta of 0.64. The company’s fifty day moving average price is $155.57 and its two-hundred day moving average price is $146.29.

DexCom (NASDAQ:DXCM) last issued its earnings results on Wednesday, November 6th. The medical device company reported $0.65 EPS for the quarter, topping analysts’ consensus estimates of $0.20 by $0.45. DexCom had a positive return on equity of 10.41% and a negative net margin of 13.96%. The firm had revenue of $396.30 million for the quarter, compared to the consensus estimate of $348.99 million. During the same quarter in the prior year, the business earned $0.17 earnings per share. The company’s revenue was up 48.6% compared to the same quarter last year. Analysts forecast that DexCom will post 0.94 earnings per share for the current year.

In related news, Director Nicholas Augustinos sold 1,208 shares of the company’s stock in a transaction dated Thursday, November 7th. The stock was sold at an average price of $185.29, for a total value of $223,830.32. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, SVP Heather S. Ace sold 7,243 shares of the company’s stock in a transaction dated Friday, August 23rd. The stock was sold at an average price of $174.80, for a total value of $1,266,076.40. The disclosure for this sale can be found here. Insiders sold a total of 105,222 shares of company stock valued at $16,407,406 in the last ninety days. 1.80% of the stock is currently owned by insiders.

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in DXCM. Cortina Asset Management LLC acquired a new position in DexCom in the 2nd quarter worth about $263,000. Silverleafe Capital Partners LLC acquired a new position in shares of DexCom during the second quarter valued at approximately $474,000. Sanders Morris Harris LLC acquired a new position in shares of DexCom during the second quarter valued at approximately $759,000. Campbell & CO Investment Adviser LLC acquired a new position in shares of DexCom during the second quarter valued at approximately $479,000. Finally, Chicago Capital LLC raised its holdings in shares of DexCom by 1.2% during the second quarter. Chicago Capital LLC now owns 194,673 shares of the medical device company’s stock valued at $29,170,000 after acquiring an additional 2,357 shares during the last quarter. 96.19% of the stock is owned by institutional investors.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company offers its systems for ambulatory use by people with diabetes; and for use by healthcare providers. Its products include DexCom G6, a CGM system for diabetes management; DexCom G5 mobile CGM system to communicate directly to patient's mobile device; DexCom G4 PLATINUM system for continuous use by adults with diabetes; and DexCom Share, a remote monitoring system.

Featured Article: Stock Symbols, CUSIP and Other Stock Identifiers

The Fly

Analyst Recommendations for DexCom (NASDAQ:DXCM)

Receive News & Ratings for DexCom Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DexCom and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Robert W. Baird Increases DexCom  Price Target to $240.00
Robert W. Baird Increases DexCom Price Target to $240.00
Elementeum Reaches One Day Volume of $1,102.00
Elementeum Reaches One Day Volume of $1,102.00
MktCoin  Achieves Market Cap of $218,176.00
MktCoin Achieves Market Cap of $218,176.00
Emphy Reaches Market Cap of $75,011.00
Emphy Reaches Market Cap of $75,011.00
$33.99 Million in Sales Expected for Urstadt Biddle Properties Inc  This Quarter
$33.99 Million in Sales Expected for Urstadt Biddle Properties Inc This Quarter
Norwegian Cruise Line  Issues  Earnings Results
Norwegian Cruise Line Issues Earnings Results


© 2006-2019 Ticker Report